FDA licensed Heplisav-B, the new hepatitis B vaccine from Dynavax, for use in adults age 18 and older
On Nov. 9, 2017, the FDA licensed Heplisav-B, the new hepatitis B vaccine, to Berkeley-based Dynavax Technologies for use in adults age 18 and older.
Tags:
Source: Dynavax Technologies
Credit:
